| 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative D Aletaha, T Neogi, AJ Silman, J Funovits, DT Felson, CO Bingham III, ... Arthritis & rheumatism 62 (9), 2569-2581, 2010 | 14521 | 2010 |
| Infliximab and methotrexate in the treatment of rheumatoid arthritis PE Lipsky, DMFM van der Heijde, EW St. Clair, DE Furst, FC Breedveld, ... New England Journal of Medicine 343 (22), 1594-1602, 2000 | 4027 | 2000 |
| Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis JCW Edwards, L Szczepański, J Szechiński, A Filipowicz-Sosnowska, ... New England Journal of Medicine 350 (25), 2572-2581, 2004 | 3419 | 2004 |
| Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase … R Maini, EW St Clair, F Breedveld, D Furst, J Kalden, M Weisman, ... The Lancet 354 (9194), 1932-1939, 1999 | 3100 | 1999 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 3086 | 2017 |
| Treating rheumatoid arthritis to target: recommendations of an international task force JS Smolen, D Aletaha, JWJ Bijlsma, FC Breedveld, D Boumpas, ... Annals of the rheumatic diseases 69 (4), 631-637, 2010 | 2887 | 2010 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update JS Smolen, R Landewé, FC Breedveld, M Buch, G Burmester, ... Annals of the rheumatic diseases 73 (3), 492-509, 2014 | 2873 | 2014 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2569 | 2020 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs JS Smolen, R Landewé, FC Breedveld, M Dougados, P Emery, ... Annals of the rheumatic diseases 69 (6), 964-975, 2010 | 2378 | 2010 |
| Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial … SB Cohen, P Emery, MW Greenwald, M Dougados, RA Furie, ... Arthritis & Rheumatism 54 (9), 2793-2806, 2006 | 2247 | 2006 |
| American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials DT Felson, JS Smolen, G Wells, B Zhang, LHD Van Tuyl, J Funovits, ... Arthritis & Rheumatism 63 (3), 573-586, 2011 | 1858 | 2011 |
| Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force JS Smolen, FC Breedveld, GR Burmester, V Bykerk, M Dougados, ... Annals of the rheumatic diseases 75 (1), 3-15, 2016 | 1637 | 2016 |
| Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci EA Stahl, S Raychaudhuri, EF Remmers, G Xie, S Eyre, BP Thomson, Y Li, ... Nature genetics 42 (6), 508-514, 2010 | 1557 | 2010 |
| Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial EW St. Clair, DMFM Van Der Heijde, JS Smolen, RN Maini, JM Bathon, ... Arthritis & Rheumatism 50 (11), 3432-3443, 2004 | 1547 | 2004 |
| 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis J Braun, R van den Berg, X Baraliakos, H Boehm, R Burgos-Vargas, ... Annals of the rheumatic diseases 70 (6), 896-904, 2011 | 1500 | 2011 |
| The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double‐blind, placebo … P Emery, R Fleischmann, A Filipowicz‐Sosnowska, J Schechtman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 1462 | 2006 |
| Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig JM Kremer, R Westhovens, M Leon, E Di Giorgio, R Alten, S Steinfeld, ... New England Journal of Medicine 349 (20), 1907-1915, 2003 | 1412 | 2003 |
| Birmingham vasculitis activity score (BVAS) Dim system necrotizinig vasculitis RA Luqmani, PA Bacon, RJ Moots, BA Janssen, A Pall, P Emery, ... QJM: An International Journal of Medicine 87 (11), 671-678, 1994 | 1402 | 1994 |
| Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist B Bresnihan, JM Alvaro‐Gracia, M Cobby, M Doherty, Z Domljan, P Emery, ... Arthritis & Rheumatism 41 (12), 2196-2204, 1998 | 1384 | 1998 |
| New therapies for treatment of rheumatoid arthritis JS Smolen, D Aletaha, M Koeller, MH Weisman, P Emery The lancet 370 (9602), 1861-1874, 2007 | 1349 | 2007 |
Dennis McGonagle PhD FRCPIUniverisity of LeedsVerified email at LEEDS.AC.UK
